About Megafine
Megafine is a Healthcare company based in Mumbai (India) founded in 1995 by Hasmukh Gandhi, Shailesh Sanghvi, and Ashok Jhaveri, and was acquired by Motilal Oswal in February 2025. Company manufacturing its own Active Pharmaceutical Ingredients (APIs) and Advanced Intermediates, and also offering CDMO services for innovator and generic pharma companies. The company has 695 employees. Its Indian entity Megafine Pharma Private Limited reported revenue of ₹310 Cr. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Its competitors include Laurus Labs, Symbiotec and Jubilant Pharma; 2 of its 3 listed competitors have raised funding.
Company details
Megafine is engaged in manufacturing its own Active Pharmaceutical Ingredients (APIs) and Advanced Intermediates, and CDMO services for several global pharma companies. It has two multipurpose manufacturing sites, both successfully inspected by US-FDA one of them is also approved by EMEA, PMDA KFDA. It has 6 APIs under consideration, 9 API products under development, 5 APIs for veterinary use and 30 APIs for human use. It also has a portfolio of 32 intermediates. It offers small batch production to commercial batch size production services as part of its contract manufacturing services. It claims to have expertise in polymorphs and chiral products. Their CDMO services are mainly catered to novel niche products in therapeutic areas such as Anthelmintic, Cardiology, Urinary Incontinence, CNS and a few others.
- Headquarters Mumbai, India
- Employees 695
- Founders Hasmukh Gandhi, Shailesh Sanghvi, Ashok Jhaveri
- Stage Acquired
- SectorsHealthcare
- Website megafine.in
- Social LinkedIn X Facebook
- Acquired by Motilal Oswal (Feb 2025)
- Legal Name Megafine Pharma Private Limited
- Date of Incorporation 22 Aug, 1995
- Jurisdiction Mumbai, Maharashtra, India
- Annual Revenue₹310 Cr
FY 2025 · -5% YoY
- Net Profit₹29.08 Cr
FY 2025 · 10% margin
- EBITDA₹50.29 Cr
FY 2025 · 17% margin
- Investors
- Employee Count695
- Acquired byMotilal Oswal
(Feb 2025)
Associated legal entities of Megafine
Megafine is associated with 2 registered companies on The Company Check; the primary company is Megafine Pharma Private Limited. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Megafine Pharma Private Limited CIN U24239MH1995PTC092028 | Active | 22 Aug 1995 | Mumbai, Maharashtra | ₹310 Cr | 758 | 3 | View details |
| Jms Venture Llp CIN AAS-5030 | Active | 28 May 2020 | Mumbai, Maharashtra | 4 | View details |
Investors in Megafine
Megafine has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Motilal Oswal Alternates.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Motilal Oswal Alternates is engaged in alternative investment management. | motilaloswalalt.com | Mumbai, India |
Investor details for Megafine
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Megafine Pharma Private Limited (Megafine)
Megafine Pharma Private Limited is the primary company behind Megafine. The boards of the 2 registered companies of Megafine currently have 6 directors; the longest-serving is Rahil Shailesh Sanghvi, appointed in 2020. 3 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Rahil Shailesh Sanghvi DIN 08748804 | Designated Partner | 28 May 2020 | 6 yrs 5 mo | Jms Venture Llp |
| Ronak Mukesh Sanghvi DIN 06745634 | Designated Partner | 28 May 2020 | 6 yrs 5 mo | Jms Venture Llp |
| Shailesh Jethmal Sanghvi DIN 00194775 | Designated Partner | 28 May 2020 | 6 yrs 5 mo | Jms Venture Llp, Megafine Pharma Private Limited |
| Mukesh Jethmal Sanghvi DIN 00334136 | Designated Partner | 28 May 2020 | 6 yrs 5 mo | Jms Venture Llp |
| Rohit Brijmohan Mantri DIN 07435803 | Nominee Director | 21 Feb 2025 | 1 yr 8 mo | Megafine Pharma Private Limited |
| Hari Prasshanth DIN 10962448 | Nominee Director | 06 Mar 2025 | 1 yr 8 mo | Megafine Pharma Private Limited |
People of Megafine
3 people are tracked at Megafine (3 in leadership); the tracked headcount is 695.
| Name | Role | Group |
|---|---|---|
| Co-Founder | Leadership | |
| Co-Founder | Leadership | |
| Co-Founder | Leadership |
Complete people profiles for Megafine
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Megafine
Figures of Megafine Pharma Private Limited, the primary company behind Megafine, for FY 2025. Revenue was ₹310 Cr (-5% year on year). Net profit was ₹29.08 Cr (10% margin). EBITDA was ₹50.29 Cr (17% margin). Revenue has grown at a compounded annual rate of +7% over three years and +11% over five years.
- ₹310 CrRevenue · FY 2025 · -5% YoY
- ₹29.08 CrNet profit · 10% margin
- ₹50.29 CrEBITDA · 17% margin
- ₹1.53 CrPaid-up capital
- 758Employees (provident fund records)
- +7%Revenue CAGR, 3 years
- +11%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Megafine Pharma Private Limited are on its company page.
Detailed financial statements for Megafine
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Megafine
2 dated milestones of Megafine across 30 years, from founding to its latest funding, stage changes and deals.
- Founded Megafine is founded.
- Exit Acquired by Motilal Oswal.
Competitors of Megafine
Megafine has 3 listed competitors in our database, 2 of them funded. They include Laurus Labs, Symbiotec and Jubilant Pharma.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lauruslabs.com | 2005 | Hyderabad, India | $229.73M | 6,035 | Pharmaceutical and biotechnology company | |
| symbiotec.in | 2002 | Indore, India | $61.01M | 1,822 | Non-sterile steroid hormone-based APIs and intermediates are manufactured. | |
| jubilantpharma.com | 1978 | Noida, India | Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company. |
Detailed competitors of Megafine
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Megafine
Websites that share an audience with Megafine (megafine.in).
Websites whose visitors overlap most with Megafine. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| harmanfinochem.com | 100% | 1.4K | #9,678,229 | View details | |
| pernixpharma.hu | 94% | View details | |||
yamanouchi.sk | yamanouchi.sk | 94% | – | ||
astellas.ca | astellas.ca | 93% | – | ||
| aartidrugs.co.in | 93% | 8.3K | #3,187,227 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Megafine
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Megafine (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 2,062 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 548 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 557 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Megafine
Complete news archive for Megafine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Megafine
Megafine was founded in 1995.
Megafine is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Megafine has 695 employees.
The primary company behind Megafine, Megafine Pharma Private Limited, reported revenue of ₹310 Cr for FY 2025, down 5% year on year.
Megafine is engaged in manufacturing its own Active Pharmaceutical Ingredients (APIs) and Advanced Intermediates, and CDMO services for several global pharma companies. It has two multipurpose manufacturing sites, both successfully inspected by US-FDA one of them is also approved by EMEA, PMDA KFDA. It has 6 APIs under consideration, 9 API products under development, 5 APIs for veterinary use and 30 APIs for human use. It also has a portfolio of 32 intermediates. It offers small batch production to commercial batch size production services as part of its contract manufacturing services. It claims to have expertise in polymorphs and chiral products. Their CDMO services are mainly catered to novel niche products in therapeutic areas such as Anthelmintic, Cardiology, Urinary Incontinence, CNS and a few others.
Megafine's top competitors include Laurus Labs, Symbiotec and Jubilant Pharma.
Megafine has 1 investor. Key investors include Motilal Oswal Alternates.
Megafine is associated with 2 legal entities: Megafine Pharma Private Limited, Jms Venture Llp.
Yes. Megafine was acquired by Motilal Oswal in February 2025.
The legal entities of Megafine currently have 6 directors, including Rahil Shailesh Sanghvi, Ronak Mukesh Sanghvi, Shailesh Jethmal Sanghvi and others.